Shandong Xinhua Pharmaceutical Management
Management criteria checks 3/4
Shandong Xinhua Pharmaceutical's CEO is Wenhui Xu, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is CN¥1.52M, comprised of 93.8% salary and 6.2% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth HK$3.42M. The average tenure of the management team and the board of directors is 5 years and 4 years respectively.
Key information
Wenhui Xu
Chief executive officer
CN¥1.5m
Total compensation
| CEO salary percentage | 93.8% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28
Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥449m |
| Jun 30 2024 | n/a | n/a | CN¥492m |
| Mar 31 2024 | n/a | n/a | CN¥487m |
| Dec 31 2023 | CN¥2m | CN¥1m | CN¥497m |
| Sep 30 2023 | n/a | n/a | CN¥510m |
| Jun 30 2023 | n/a | n/a | CN¥486m |
| Mar 31 2023 | n/a | n/a | CN¥454m |
| Jan 01 2023 | n/a | n/a | CN¥411m |
| Sep 30 2022 | n/a | n/a | CN¥357m |
| Jun 30 2022 | n/a | n/a | CN¥343m |
| Mar 31 2022 | n/a | n/a | CN¥357m |
| Dec 31 2021 | CN¥1m | n/a | CN¥349m |
| Sep 30 2021 | n/a | n/a | CN¥364m |
| Jun 30 2021 | n/a | n/a | CN¥353m |
| Mar 31 2021 | n/a | n/a | CN¥339m |
| Dec 31 2020 | CN¥829k | n/a | CN¥325m |
Compensation vs Market: Wenhui's total compensation ($USD208.52K) is below average for companies of similar size in the Hong Kong market ($USD478.20K).
Compensation vs Earnings: Wenhui's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Wenhui Xu (47 yo)
2.3yrs
Tenure
CN¥1,521,382
Compensation
Mr. Wenhui Xu serves as Executive Director and General Manager of Shandong Xinhua Pharmaceutical Company Limited since October 27, 2022 and September 19, 2022 respectively. He served as the Deputy General...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Deputy GM | 4yrs | CN¥1.61m | 0.043% HK$ 4.1m | |
| GM & Executive Director | 2.3yrs | CN¥1.52m | 0.035% HK$ 3.4m | |
| CFO, Financial Controller & Executive Director | 10.7yrs | CN¥1.28m | 0.048% HK$ 4.6m | |
| Deputy General Manager | 7.8yrs | CN¥1.41m | 0.043% HK$ 4.1m | |
| Deputy GM & Manager of Administrative Personnel Department | no data | CN¥1.41m | 0.035% HK$ 3.4m | |
| Deputy General Manager | 2.3yrs | CN¥831.80k | 0.013% HK$ 1.3m | |
| Company Secretary | 27.4yrs | CN¥446.80k | 0.029% HK$ 2.8m | |
| Deputy General Manager | 2.3yrs | CN¥1.10m | 0.011% HK$ 1.0m | |
| Head of Accounting Department | no data | no data | no data | |
| Chief of Finance Department | no data | no data | no data |
5.0yrs
Average Tenure
51yo
Average Age
Experienced Management: 719's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & Deputy GM | 4yrs | CN¥1.61m | 0.043% HK$ 4.1m | |
| GM & Executive Director | 2.2yrs | CN¥1.52m | 0.035% HK$ 3.4m | |
| CFO, Financial Controller & Executive Director | 2.2yrs | CN¥1.28m | 0.048% HK$ 4.6m | |
| Independent Supervisor | 22.5yrs | CN¥20.00k | no data | |
| Non-Executive Director | 14.5yrs | CN¥1.41m | 0.043% HK$ 4.1m | |
| Employee Supervisor | 13.4yrs | CN¥101.00k | no data | |
| Independent Non-Executive Director | 4yrs | CN¥100.00k | no data | |
| Chairman of Supervisory Committee | 4yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 2.2yrs | CN¥58.33k | no data | |
| Non-Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
4.0yrs
Average Tenure
54yo
Average Age
Experienced Board: 719's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alex Fan | GF Securities (Hong Kong) Brokerage Limited |
| Ming Li | Industrial Securities Co. Ltd. |
| Guohe Fan | Phillip Securities (HK) |